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Bridging the Gap in Pharmacoeconomics and Outcomes Research
between Researchers, Policymakers, and Practitioners in the Asia-
Pacific RegionWithin the past decade in the Asia-Pacific region, pharmacoeco-
nomics (PE) disciplines have been recognized as an important sci-
ence among researchers, policy decision makers, and health-care
practitioners. The growing number of participants at the past IS-
POR Asia-Pacific conferences, especially the ISPOR 4th Asia-Pacific
Conference held in Thailand from September 5 to 7, 2010, could be
supporting evidence. At present, it is widely accepted in this re-
gion that economic evaluation of medical and public health inter-
ventions is one of the most important tools needed to ensure effi-
cient and equitable use of medical and public health technology.
Nevertheless, several barriers can be explored and compared with
other regions in the world, not only to obtain knowledge about PE
disciplines but also to find the pivotalmeans to enhance its use for
policy decision makers in real-world health-care resource alloca-
tion.
Following the ISPOR 1st and 2nd Asia-Pacific conferences,
which took place in Japan (Kobe) and China (Shanghai), respec-
tively, South Korea (Seoul) and Thailand (Phuket) hosted the ISPOR
3rd and 4th Asia-Pacific conferences. Taiwan (Taipei) was chosen
to hold the ISPOR 5th Asia-Pacific conference in 2012. It was re-
ported that in these Asia-Pacific regions, Korea, Thailand, and Tai-
wan have beenmoving toward policies to fully implement the use
of PE into their universal health insurance schemes. The settings
in which ISPOR Asia-Pacific conferences have taken place have
also developed evidence indicating that there exists greater inten-
sity of PE use in their countries. The progress of the use of PE
among those and other countries in this region can be found in the
past two Value in Health Asia special issues [1,2] and in this third
Asia issue: Value in Health, Volume 15, Supplement 1 (January/Feb-
ruary 2012).
The information from this issue may well signify characteris-
tics of PE use in the Asia region, which certainly differs from other
regions in the world. Although various factors can be attributed to
the use of PE, the ISPOR 4th Asia-Pacific Conference paid attention
to several factors including, but not limited to, the health-care
reimbursement system, health-care information data, and na-
tional drug formulary.
Health-care reimbursement systems for pharmaceuticals have
been recognized as one of themost important factors. Health-care
reimbursement inAsia varies on the basis of the specific context of
health-care system in each country. Actually, the health insur-
ance system is the major driving force that can shape the health-
care reimbursement system for pharmaceuticals. In places where
universal health coverage exists, such as Korea, Thailand, and
Taiwan, there has been continuous progress in the development
of PE evaluation or health technology assessment (HTA) systems.Conflicts of interest: The authors have indicated that they have noThe benefit of using PE or HTA has been illustrated by the advan-
tage of selecting essential medicines that can ensure efficiency
and equity aspects in health-care delivery. PE or HTAprovide valu-
able information on both resource use and expected outcome,
which are, inmost cases, expressed as quantifiedmeasures; there-
fore, it is easier to compare among alternative interventions. Thus,
cost-effectiveness data allowdecisionmakers to come to objective
judgments based on scientifically measured benefit of compara-
tive interventions. Certainly, the limitation of other factors, in-
cluding development and implementation of drug policy, human
resources, PE knowledge, PE expertise, PE data source, and funding
for PE or HTA, can be accounted for the delay in the development
of providing PE evidence for decision makers. Achieving universal
coverage, however, can reduce these limitations and also increase
the demand for PE studies in providing useful information for de-
cision making. Experience in the use of PE for decision makers in
the Asia region, who adopted the economic evaluation systemand
use PE results at the national level, can encourage other countries
to share the predecessors’ experiences and find their own ways to
tailor the system for their countries.
The development of health-care information seems to be an
important factor in enhancing the use of PE. PE data from actual
practice represent the real situation of the population for which
the decision for health-care benefit needs to be taken. Improving
the data system will provide more opportunities for health econ-
omists and outcomes researchers to conduct research that sup-
ports HTA and helps in health policy making. Not only the avail-
ability of data can help improve the PE research, but the quality
and transparency of data can also advance the quality of PE stud-
ies for decision makers. Most countries in Asia have a noninte-
grated data-inflow system, even within the same institution.
Merging data even within the same institution is still a challenge
in some places, while others show progress in the availability of a
computerized system that can transfer and merge data for the
specific objective of PE research. Data sources that differ from
place to place impede the benefit of using them together for gen-
eralizing obtained results to other jurisdictions. This barrier can be
lowered by progress in the availability of reliable health-care data
for PE studies at the national level.
The use of drug and medical technology will depend on how
well they are covered by health insurance or by public health ben-
efit packages. Their use is highly restricted in a system where out
of pocket is a predominant formof health financing. Drugs ormed-
ical technologies that are covered by the health insurance benefit
package will certainly be used more. In Japan, China, Thailand,
Korea, and Taiwan, selecting drugs will be an important gatewayconflicts of interest with regard to the content of this article.
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formulary list at the national level where economic evaluation is
used for reimbursement justification. Nevertheless, the use of PE
in the national drug list should be further developed in theseAsian
health-care systems, and experience fromeachneeds to be shared
among others to help implement the policy of utilizing PE data for
the system. Fortunately, much has been learned from the ISPOR
4thAsia-Pacific Conference about the criteria of listing drugs at the
national level in several countries and how PE and outcomes re-
search is used in the formulary decision. Almost all the evidence-
based research results discussed in this issue, which demonstrate
the progress of PE use, have been selected from a number of ab-
stracts and proposals, including poster and oral presentations and
workshops, presented at the ISPOR 4th Asia-Pacific Conference.
From 413 submitted abstracts and proposals, 368 (89.1%) were ac-
cepted. Of these, 340 were accepted for podium (40) and poster
(300) presentations, 15 for workshops, 9 for issue panels, and 4 for
decision-makers’ case studies.
Regarding submissions for thisValue in Health third Asia special
issue, the total number of submissionswas 115, including 3 invited
health policy articles that were developed on the basis of three
plenary sessions. All the 115 articles were reviewed by three or
more reviewers. The Value in Health peer review criteria were used
for this publication. In the first round of editorial decisions, 60
manuscripts were rejected (one was found unsuitable for this spe-
cial issue because of the study population being outside of Asia)
and 55 were recommended for revision, including the 3 plenary
articles.
Among the 55 recommendedmanuscripts, authors of 5 manu-
scripts withdrew their manuscripts from further consideration
and the remaining 50 were revised for reconsideration. All revised
articles were sent to the same reviewers for a second review, with
the exception of the three plenary articles that needed to be re-
written. In the second round of editorial decision process, 20 arti-
cles were accepted for publication. These 20 articles are on eco-
nomic evaluation (9 articles), health policy analysis (6 articles),
patient-reported outcomes (4 articles), and preference-based as-
sessment (1 article), and they are from Thailand, Taiwan, South
Korea, Singapore, China, Japan, Malaysia, and India. The three
plenary articles were recommended for publication as “commen-
tary.”
Each Asia-Pacific conference has its role to fill the gap between
the PE knowledge and the use of PE by policy decisionmakers. The
ISPOR 4th Asia-Pacific Conference demonstrated its role by the
theme of the conference: Bridging the Gap in Pharmacoeconomicsand Outcomes Research between Researchers, Policymakers, and
Practitioners.There is no doubt that the articles that appear in this
issue reflect an addition to the knowledge obtained at the confer-
ence.
We look forward to participating at the ISPOR 5th Asia-Pacific
Conference, to be held in Taiwan, from September 2 to 4, 2012.
Researchers, policymakers, and practitioners in the Asia-Pacific
region who are interested in PE and outcomes research should
once again gather to help improve the practice and use of PE and
outcomes research in this Asia-Pacific region together.
We acknowledge significant contribution from Dr. Yot Teera-
wattananon and his team from Health Intervention and Technol-
ogy Assessment Program (HITAP), Thailand, for their reviewing of
the submitted articles to be selected for publication in this issue in
the first round.
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